Plain-English translation of NCT06578078 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether can help older adults with heart failure and chronic kidney disease receive better doses of heart-protective medications safely. Many people with these conditions struggle because the most effective heart drugs can raise potassium to dangerous levels. This medication is designed to lower potassium, allowing doctors to give patients the full, most beneficial doses of their heart medicines.
Older patients with heart failure and kidney disease often can't take full doses of the most protective heart medications because of the risk of dangerously high potassium levels. This trial is testing whether the medication can solve this problem by keeping potassium safe while patients receive the treatments they need most.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either take the medication along with your regular heart medicines, or to continue with your regular heart medicines alone. The study lasts 3 months, during which your doctors will work to increase your heart-protective medications to the best doses according to current guidelines. You will have regular visits to check your potassium levels, kidney function, and how you're feeling, so your care team can monitor your safety and adjust treatments as needed.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Spain